QUIKFLO HEALTH INC.
(Formerly Viper Gold Ltd.)

CONSOLIDATED FINANCIAL STATEMENTS

For Nine Months Ended April 30, 2016
And for the Year Ended July 31, 2015

(Unaudited – Expressed in Canadian Dollars)

Notice to Readers:

These unaudited consolidated interim financial statements of QUIKFLO HEALTH INC. (Formerly Viper Gold Ltd. (the “Company”) have not been reviewed by the auditors of the Company. This notice is being provided in accordance with Section 4.3 (3) (a) of National Instrument 51-102 - *Continuous Disclosure Obligations.*

QUIKFLO HEALTH INC.

Consolidated Interim Statement of Financial Position
(Expressed in Canadian Dollars)
(Unaudited)

	Notes	As at April 30, 2016	As at July 31, 2015
		$	$
ASSETS			
Current Assets			
Cash		17,412	1
Sales tax receivable		10,512	1,790
Prepaid expenses		17,438	-
Total Current Assets		45,362	1,791
Non-current Assets			
Intangible asset	*5*	400,000	375,000
Total Assets		445,362	376,791
LIABILITIES AND SHAREHOLDERS' EQUITY			
Current Liabilities			
Accounts payable and accrued liabilities		527,663	45,079
Total Current Liabilities		527,663	45,079
Shareholders' Equity			
Share capital	*6*	1,301,710	372,555
Share based payments reserve		435,268	-
Deficit		(1,819,279)	(40,843)
Total Shareholders' Equity		(82,301)	331,712
Total Liabilities and Shareholders' Equity		445,362	376,791

Going concern (Note 2)
Commitments and contingencies (Note 11)
Subsequent events (Note 13)

Approved on Behalf of the Board:
Director

"Signed"	"Signed"
George Tsafalas	Rick Skeith

The accompanying notes are an integral part of these consolidated interim financial statements.

QUIKFLO HEALTH INC.
Consolidated Interim Statement of Loss and Comprehensive Loss
(Expressed in Canadian Dollars)
(Unaudited)

	Notes	For Nine Months period ended April 30, 2016	For Three Months period ended April 30, 2016
		$	$
Expenses			
Listing expense		**564,092**	**-**
Stock based compensation		**288,668**	**-**
Management and consulting fees		**526,377**	**169,150**
Filling fees and communications		**40,704**	**12,741**
Payroll		**54,165**	**25,062**
Professional fees		**147,934**	**6,964**
General and administrative expenses		**156,396**	**16,840**
Net loss and comprehensive loss for the period		**1,778,436**	**230,757**
Basic and diluted loss per share		(0.07)	(0.01)
Weighted average number of common shares		25,369,901	39,231,644

The accompanying notes are an integral part of these consolidated interim financial statements.

QUIKFLO HEALTH INC.
Consolidated Interim Statement of Cash Flow
(Expressed in Canadian Dollars)
(Unaudited)

	Notes	**Nine Months Ended April 30, 2016**	**Three Months Ended April 30, 2016**
			$
Cash flows from operating activities:			
Operating Activities			
Net (loss) for the period		**(1,778,436)**	**(357,524)**
Changes in non-cash components of working capital			
Listing expense		**564,092**	**-**
Stock based compensation		**288,768**	**-**
Sales tax receivable		**(8,722)**	**(9,068)**
Prepaid expenses		**3,592**	**(10,500)**
Accounts payable and accrued liabilities		**369,406**	**376,966**
Net cash flows (used in) operating activities		**(561,300)**	**(125)**
Cash flows from financing activities			
Issue of common shares, Net		**6,255**	**67,960**
Cash acquired related to RTO		**572,456**	**-**
Net cash flows (used in) financing activities		**578,711**	**67,960**
Increase in cash		**17,411**	**67,835**
Cash, beginning of the period		**1**	**62,723**
Cash, end of the period		**17,412**	**130,558**

The accompanying notes are an integral part of these consolidated interim financial statements.

QUIKFLO HEALTH INC.
Consolidated Interim Statement of Changes in Equity
(Expressed in Canadian Dollars)
(Unaudited)

		Share capital					
	Notes	**Number of shares**	**Amount**	**Warrants**	**Share-based Payments Reserve**	**Deficit**	**Total equity**
			$	**$**	**$**	**$**	
Balance at July 31, 2015		601	372,555			(40,843)	331,712
Reverse takeover (RTO) transaction	*5*	*(601)*	-	-	-	-	-
RTO acquisition of QuikFlo Technologies	*5*	*30,000,000*	-	-	-	-	-
QuikFlo Health shares on RTO	*5*	*8,576,599*	858,600	-	-	-	858,600
RTO assumption of QuikFlo Health warrants	*5*	-	-	185,800	-	-	185,800
Common shares issued for warrants exercise		700,000	74,300	(39,300)	-	-	35,000
Share issued for license acquisition		100,000	25,000	-	-	-	25,000
Share issue costs		-	(28,745)	-	-	-	(28,745)
Stock based Compensation		-	-	288,768		-	288,768
Net loss for the period		-	-		-	(1,778,436)	(1,778,436)
Balance at April 30, 2016		39,377,200	1,301,710	435,268		(1,819,279)	(82,301)

The accompanying notes are an integral part of these consolidated interim financial statements.

1. NATURE OF OPERATIONS

Viper Gold Ltd. (the "Company") was incorporated pursuant to the provisions of the Business Corporations Act (Alberta) on January 29, 2008. The Company's executive office is located at 430 – 580 Hornby Street, Vancouver, British Columbia, Canada. Viper Gold Ltd. (the "Company") changed its name to QuikFlo Health Inc. on November 23, 2015. The Company was in the business of acquiring and exploring mineral properties. The Company has recently acquired a company in the medical diagnostic field. QuikFlo is a medical software company developing innovative solutions for the analysis of medical images. Our primary focus is on improving outcomes for stroke patients, where existing time delays are solvable through more efficient triage based on rapid, accurate analysis of medical images.

As certain directors and officers of QuikFlo Health (Formerly Viper) are also shareholders and officers of QuikFlo Technologies Inc., an independent valuation was obtained which places the value of QuikFlo Technologies Inc. in a range of $2.9 million to $3.4 million. In conjunction with the Transaction, the Company also raised $500,000 in a non-brokered private placement of QuikFlo Health Inc. (Formerly Viper) Shares at $0.25 per share (the "Private Placement"). The proceeds of the Private Placement will be used to develop the QuikFlo Diagnostic Tool and to pay for a portion of the costs of the Transaction.

QuikFlo Technologies Inc. was incorporated by the QuikFlo Technologies Inc. shareholders to acquire the QuikFlo Diagnostic Tool from UTI Limited Partnership, operating as Innovate Calgary ("Innovate Calgary"), the technology transfer and commercialization entity of the University of Calgary, for the purpose of developing and commercializing the associated intellectual property. The QuikFlo Diagnostic Tool was acquired by QuikFlo Technologies Inc. pursuant to an arm's length assignment agreement (the "Assignment Agreement") between QuikFlo Technologies Inc. and Innovate Calgary dated July 27, 2015. The Assignment Agreement provides for the assignment to QuikFlo Technologies of Innovate Calgary's right, title and interest in and to the intellectual property and technology rights associated with the QuikFlo Diagnostic Tool in consideration for the grant of a license to Innovate Calgary to use the QuikFlo Diagnostic Tool for non-commercial purposes, including publication of scientific findings, education and further research. In addition, QuikFlo Technologies Inc. agreed to pay a royalty to Innovate Calgary on the gross sales revenue received by QuikFlo Technologies Inc. in relation to any product, process or service derived from the QuikFlo Diagnostic Tool. Further, QuikFlo Technologies Inc. is obligated to pay a change of control fee upon certain defined liquidation events. The rights associated with the QuikFlo Diagnostic Tool can revert to Innovate Calgary upon the bankruptcy or insolvency of QuikFlo Technologies Inc. or upon its default under certain provisions of the Assignment Agreement.

The Quikflo Technologies Inc. acquisition closed on November 23, 2015. QuikFlo Health Inc. will carry on as the continuing entity under the name "QuikFlo Health Inc." ("Resulting Issuer").

Following the Transaction, the Resulting Issue adopted the fiscal year end of QuikFlo Technologies being July 31. The first financial year-end after Transaction will be July 31, 2016.

On February 12, 2016 the Company has reached agreement to enter into a worldwide non-exclusive license agreement with the University of Western Ontario ("Western") to use certain CT perfusion intellectual property that has been developed by Dr. Ting Lee, the Company's former Chief Technology Officer. This technology was assigned to Western by Dr. Lee, who is a professor at Western, in accordance with that university's policies. This same technology has been an integral part of General Electric's CT scanner programs for several years.

2. GOING CONCERN

The Company was in the exploration and evaluation stage and up to May 8, 2014, it held an interest in certain mineral claims in Peru from which no revenue had been generated. The exploration and development of mineral properties involves significant financial risk, with recoverability of costs incurred being subject to future profitable production from economically recoverable reserves and/or financing through issuance of shares or sale of property interests. It has recently acquired a company in the medical diagnostic field.

These consolidated condensed interim financial statements have been prepared on a going concern basis which contemplates the realization of assets and the payment of liabilities in the ordinary course of business. Accordingly, they do not give effect to adjustments that would be necessary should the Company be unable to continue as a going concern and, therefore, be required to realize its assets and liquidate its liabilities and commitments in other than the normal course of business at amounts different from those in these financial statements. Such adjustments could be material. The continuing operations of the Company are dependent upon its ability to obtain the necessary financing to meet ongoing administration expenses and related liabilities as they fall due.

In assessing whether the going concern assumption is appropriate, management takes into account all available information about the future, which is at least, but is not limited to, twelve months from the end of the reporting period. Management believes they can raise sufficient working capital to continue current operations for the next twelve months, but is aware, in making its going concern assessment, of material uncertainties related to events or conditions that cast doubt upon the entity's ability to continue as a going concern. The Company has incurred a loss in the current and prior periods, with a loss of $1,778,436 for the nine month period ended April 30, 2016, and as April 30, 2016 has an accumulated deficit of $1,819,279 (July 31, 2015 - $40,843) and a working capital deficiency of $482,301 (July 31, 2015 – working capital of $43,228).

3. BASIS OF PRESENTATION

(a) Statement of compliance

These condensed interim consolidated financial statements have been prepared in accordance with *International Financial Reporting Standards* ("IFRS") as issued by the *International Accounting Standards Board* ("IASB") applicable to the preparation of interim financial statements, including *International Accounting Standards* ("IAS") 34, *Interim Financial Reporting*. The unaudited interim condensed consolidated financial statements should be read in conjunction with the Company's annual audited consolidated financial statements for the year ended December 31, 2015. These financial statements were approved and authorized for issue by the Board of Directors on June 28, 2016.

(b) Acquisition of QuikFlo Health – Reverse Takeover

On November 23, 2015, QuikFlo Helath acquired a 100% ownership in QuikFlo Technologies by issuing 30,000,000 common shares to the shareholders of QuikFlo Technologies (Note 5). For accounting purposes, this acquisition is accounted for as a reverse takeover transaction and recapitalization because the acquisition resulted in the former shareholders of QuikFlo Technologies having control of the combined entity. This was accounted for as an acquisition of assets of QuikFlo Health and is not a business combination. Accounting for the acquisition as a reverse takeover results in the following:

i. The consolidated financial statements of the combined entities are issued as the consolidated financial statements of the legal parent, Contagious Gaming, but are considered a continuation of the financial statements of the legal subsidiary, QuikFlo Technologies
ii. Since QuikFlo Technologies is deemed to be the acquirer for accounting purposes, its assets and liabilities are included in the consolidated financial statements at their historical carrying values.
iii. The deficit of QuikFlo Health up to the date of acquisition was eliminated.
iv. The number of shares issued in the consolidated entity is that of QuikFlo Health up to the RTO date on November 23, 2015, plus all shares issued on and after the RTO date. The dollar amount of the issued share capital in the consolidated statement of financial position immediately prior to acquisition is the dollar value of QuikFlo Technologies' issued capital up to the RTO date on November 23, 2015 plus the value of all shares issued by the Company on and after the RTO date, including the value of shares issued to acquire QuikFlo Technologies.
v. Change of fiscal year end from December 31 to March 31 to coincide with the fiscal year end of QuikFlo Technologies.

4. SIGNIFICANT ACCOUNTING POLICIES

These unaudited interim condensed consolidated financial statements have been prepared using the same policies and methods as the annual consolidated financial statements of the Corporation for the year ended December 31, 2015. Refer to note 3 and 4 of the Corporation's audited consolidated financial statements for the period ended July 31, 2015 for more information on new accounting standards and amendments not yet effective.

5. AQUISITION OF QUIKFLO TECHNOLOGIES INC.

On November 23, 2015, QuikFlo Health acquired a 100% ownership in QuikFlo Technologies by issuing 30,000,000 common shares to the shareholders of QuikFlo Technologies (Note 1). For accounting purposes, this acquisition is accounted for as a reverse takeover transaction and recapitalization because the acquisition resulted in the former shareholders of QuikFlo Technologies having control of the combined entity. This was accounted for as an acquisition of assets of QuikFlo Health and is not a business combination.

The fair value of the consideration paid by QuikFlo Technologies for the acquisition of QuikFlo Heal this based on the fair value of equity instruments in the combined entities allocated to the existing shareholders in QuikFlo Health. The consideration paid by QuikFlo Technologies consists of the fair value of QuikFlo Health's common shares, share purchase options and share purchase warrants outstanding immediately before the date of the reverse takeover acquisition. The identifiable assets acquired and liabilities of QuikFlo Health assumed by QuikFlo Technologies are measured at their fair values at the acquisition date. Excess of the aggregate of the consideration transferred by QuikFlo Technologies over the fair value of the identifiable net assets acquired and liabilities of QuikFlo Health assumed by QuikFlo Technologies is attributable to the cost of obtaining a listing status. This amount is expensed as it does not meet the criteria for recognition as an asset.

The following are the fair values of QuikFlo Health's assets acquired and liabilities assumed by QuikFlo Technologies on November 23, 2015 and consideration paid by QuikFlo Technologies:

(Unaudited - Expressed in Canadian dollars)

Net Assets (liabilities) acquired	
Cash	572,456
Prepaid expenses	21,030
Accounts payable and accrued liabilities	(113,178)
	480,308
Consideration paid	
Fair value of QuikFlo Health's existing common shares deemed issued by QuikFlo Technologies	858,600
Fair value of QuikFlo Health's existing post consolidation share purchase warrants deemed granted by QuikFlo Technologies	185,800
	1,044,400
Listing expense	$564,092

The fair value of QuiKFlo Health's share purchase warrants assumed by QuikFlo Technologies were valued using the Black-Scholes option pricing model with the following weighted average assumptions:

Stock price volatility	100%
Risk free interest rate	0.47%
Expected life	0.7 years
Expected dividend yield	0.00%

6. SHARE CAPITAL AND OTHER EQUITY

(i) Authorized, issued and outstanding shares

Authorized:
- unlimited number of common shares without par value
- unlimited number of preferred shares issuable in series

(ii) Private placements

Immediately prior to the reverse takeover QuikFlo Health closed a non-brokered private placement for 2,000,000 common shares at a price of $0.25 per common share, for aggregate gross proceeds of $500,000.

(Unaudited - Expressed in Canadian dollars)

On November 23, 2015 the Company issued 30,000,000 common shares for acquisition of QuikFlo Technologies Inc.

During the nine month period the Company issued 700,000 common shares for warrants exercising for total proceeds $35,000.

The Company issued to the University of Western Ontario 100,000 common shares for the license acquisition.

(iii) Warrants

Details of common share purchase warrants outstanding at April 30, 2016 are as follows:

	Number of Warrants	Exercise Price	Expiry Date	Grant Date Fair Value
Share purchase warrants:				
Issued on private placement	2,550,000	$0.05	July 14, 2016	$ 39,031
	2,550,000			$ 39,031

Common share purchase warrant transactions during the nine months ended April 30, 2016 and for the year ended July 31, 2015 are as follows:

	April 30, 2016			July 31, 2015		
	Number of Warrants	Weighted Average Exercise Price	Grant Date Fair Value	Number of Warrants	Weighted Average Exercise Price	Grant Date Fair Value
Outstanding – beginning of the year	595,000	$ 1.00	$ 4,598	595,000	$ 0.50	$ 4,598
Issued	3,306,000	0.05	45,693	-	-	-
Expired/Exercised	(1,351,000)	0.35	(11,260)	-	-	-
Outstanding – end of the period	2,550,000	$ 0.05	$ 39,031	595,000	$ 1.00	$ 4,598

The warrants issued in 2014 were exercisable at $0.50 to July 10, 2014 and thereafter at $1.00 until July 10, 2015. On July 10, 2015 these warrants expired unexercised.

The grant date fair value of the 56,000 finders' warrants issued in connection with the private placement that closed on March 4, 2015 has been estimated at $539, using the Black-Scholes option pricing model. The following weighted average assumptions were used: Risk-free interest rate – 0.59%; Expected volatility – 100%; Expected dividend yield – nil; Expected life – 1 year. On March 4, 2016 56,000 finder's warrants expired unexercised.

(Unaudited - Expressed in Canadian dollars)

The grant date fair value of the 3,250,000 warrants issued in connection with the private placement that closed on July 14, 2015 has been estimated at $45,154, using the Black-Scholes option pricing model. The following weighted average assumptions were used: Risk-free interest rate – 0.45%; Expected volatility – 100%; Expected dividend yield – nil; Expected life – 1 year.

The weighted average remaining contractual life of the issued and outstanding warrants as at January 31, 2016 was 0.8 years. On January 2016 300,000 warrants issued on July 14, 2015 were exercised. On February 2016 400,000 warrants issued on July 14, 2015 were exercised.

7. SHARE - BASED PAYMENTS – SHARE OPTION PLAN

The Company has adopted a stock option plan (the "Plan") for its directors, officers, employees and consultants to acquire common shares of the Company at a price determined by the fair market value of the shares at the date immediately preceding the date on which the option is granted. The terms and conditions of the options are determined by the Board of Directors.

The aggregate number of common stock options shall not exceed 20% of the issued and outstanding common shares of the Company, with no one individual being granted more than 5% of the issued and outstanding common shares. In addition, the exercise price of options granted under the plan shall not be lower than the exercise price permitted by the TSX Venture Exchange, and all options granted under the plan will have a term not to exceed five years.

A summary of the status of the Plan as at April 30, 2016 and July 31, 2015, and changes during periods ended on those dates are presented below:

	April 30, 2016		July 31, 2015	
	Number Of stock Options	Weighted Average Exercise Price	Number Of stock Options	Weighted Average Exercise Price
Outstanding – beginning of the year	65,600	$3.40	65,600	$3.40
Granted	4,700,000	0.25	-	-
Expired	(65,600)	$3.40	-	$ -
Outstanding – end of the period	4,700,000	$0.25	65,600	$3.40

(Unaudited - Expressed in Canadian dollars)

The following table summarizes stock options outstanding and exercisable under the Company's stock option plan as at April 30, 2016:

Expiry date	Options Exercisable & Outstanding*	Exercise Price per share ($)	Grant date Fair Value of Options ($)
Nov 14, 2021	4,275,000	0.25	262,656
Nov 24, 2021	100,000	0.25	6,144
Nov 25, 2021	150,000	0.25	9,216
Dec 23, 2021	100,000	0.25	6,144
Jan 8, 2022	75,000	0.25	4,608
	4,700,000	0.25	288,768

8. LOSS PER SHARE

(a) Basic

Basic loss per share is calculated by dividing the net loss attributable to common shareholders by the weighted average number of common shares issued and outstanding during the nine months and three months period ended April 30, 2016.

	For the three months ended April 30, 2016	For the nine months ended April 30, 2016
Net loss attributable to common shareholders	$ (230,739)	$ (1,778,436)
Weighted average number of ordinary shares in issue	39,231,644	25,369,901
Basic loss per share	$ (0.01)	$ (0.07)

(b) Diluted

Diluted loss per share is the same as basic loss per share as issued and outstanding warrants and options are considered to be anti-dilutive.

9. FINANCIAL RISK MANAGEMENT

The Company's risk exposures and the impact on the Company's financial instruments are summarized below. There have been no changes in the risks, objectives, policies and procedures from the previous year.

(a) Credit risk management

Credit risk is the risk of loss associated with counterparty's inability to fulfill its payment obligations. The Company's credit risk is primarily attributable to cash and amounts receivables. Cash is held with a reputable Canadian financial institution, from which management believes the risk of loss is remote. Financial instruments included in amounts receivable consist of harmonized sales tax due from the Federal Government of Canada. Management believes that the credit risk concentration with respect to financial instruments included in amounts receivable is minimal.

(b) Liquidity risk

As at April 30, 2016, the Company had a working capital deficiency of $482,301 (July 31, 2015 – working capital of $43,288). The Company's approach to managing liquidity risk is to ensure that it will have sufficient liquidity to meet liabilities when due. As at April 30, 2016, the Company does not have sufficient cash to settle current liabilities.

(c) Foreign currency risk

Foreign currency risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in foreign currency rates. As at April 30, 2016, the Company had cash balances of $20 (July 31, 2015 - $Nil) in U.S. dollars. Sensitivity to a plus or minus 5% change in the foreign exchange rate would not have had a material effect to the net loss for the nine month period ended April 30, 2016. The Company does not undertake currency hedging activities to mitigate its foreign currency risk.

(d) Interest rate risk

Interest rate risk is the risk that the fair value of future cash flows of a financial instrument will fluctuate because of changes in market interest rates. The Company has cash balances and currently does not carry interest-bearing debt. The Company's current policy is to invest excess cash in investment-grade short-term deposit certificates issued by its financial institutions. It is management's opinion that the Company is not exposed to significant interest rate risk.

(e) Fair value of financial assets and liabilities

The book values of the cash, amounts receivable, and accounts payable and accrued liabilities approximate their respective fair values due to the short-term nature of these instruments.

(Unaudited - Expressed in Canadian dollars)

The fair values together with the carrying amounts shown in the statements of financial position are as follows:

	As at April 30, 2016		As at July 31, 2015	
	Carrying Amount	Fair Value	Carrying Amount	Fair Value
Cash	$ 17,412	$ 17,412	$ 1	$ 1
Sales tax receivable	10,512	10,512	1,790	1,790
Accounts payable and accrued liabilities	527,663	527,663	45,079	45,079

10. CAPITAL RISK MANAGEMENT

The Company defines capital as Shareholders' Equity which at April 30, 2016 was $1,819,279 (July 31, 2015 - $40,843). The Company manages its capital structure and makes adjustments to it, in order to have the funds available to support its exploration, development and operations activities.

The Company's objective when managing capital is to safeguard the Company's ability to continue as a going concern in order to pursue the exploration of its mineral properties and maximize shareholder returns. The Company satisfies its capital requirements through careful management of its cash resources and by utilizing bank indebtedness or equity issues, as necessary, based on the prevalent economic conditions of both the industry and the capital markets and the underlying risk characteristics of the related assets. As at April 30, 2016, the Company had no bank debt. As discussed in Note 2, the Company's ability to continue to carry out its planned operations is uncertain and dependent upon the continued financial support of its shareholders and securing additional financing.

Management reviews its capital management approach on an ongoing basis. There were no changes in the Company's approach to capital management during the nine month period ended April 30, 2016 and for the year ended July 31, 2015. The Company is not subject to externally imposed capital requirement.

(Unaudited - Expressed in Canadian dollars)

11. COMMITMENTS AND CONTINGENCIES

QuikFlo Technologies Inc. agreed to pay a royalty to Innovate Calgary on the gross sales revenue received by QuikFlo Technologies Inc. in relation to any product, process or service derived from the QuikFlo Diagnostic Tool. Further, QuikFlo Technologies Inc. is obligated to pay a change of control fee upon certain defined liquidation events.

12. COMPENSATION OF KEY MANAGEMENT AND RELATED PARTY TRANSACTIONS

The remuneration of directors and members of key management personnel during the nine month and three month periods ended April 30, 2016 was as follows:

	Nine Months Ended April 30	Three Month Ended April 30
Compensation	$ 849,308	$ 88,400
Share-based payments	288,768	-
	$ 1,138,077	$ 88,400

During the nine month period ended April 30, 2016, the Company incurred legal fees and share issue costs in the amount of $382,424 and $28,523 from a law firm of which a director of the Company is a partner. As at April 30, 2016, the Company owed the law firm $263,136. These amounts are unsecured, non-interest bearing with no fixed terms of repayment.

During the nine month period ended April 30, 2016, the former Chief Financial Officer of the Company charged the Company a total of $4,000 for services rendered as disclosed in the compensation table above. As at April 30, 2016, the Company owed the Chief Financial Officer of the Company $Nil.

During the nine month period ended April 30, 2016, the interim Chief Financial Officer of the Company charged the Company a total of $24,500 for services rendered as disclosed in the compensation table above. As at April 30, 2016, the Company owed the Chief Financial Officer of the Company $18,000. These amounts are unsecured, non-interest bearing with no fixed terms of repayment.

During the nine month period ended April 30, 2016, the Chief Executive Officer of the Company charged the Company a total of $250,010 for services rendered as disclosed in the compensation table above. As at April 30, 2016, the Company owed the Chief Executive Officer of the Company $104,585. These amounts are unsecured, non-interest bearing with no fixed terms of repayment.

During the nine month period ended April 30, 2016, the Directors and their companies of the Company charged the Company a total of $163,851 for services rendered as disclosed in the compensation table above. As at April 30, 2016, the Company owed the Directors and their companies of the Company $Nil. These amounts are unsecured, non-interest bearing with no fixed terms of repayment.